CervoMed Gains 20% on Dementia Patent, Raises $10M in Offering
CRVO•CervoMed secured a USPTO notice of allowance for its lead drug neflamapimod in dementia with Lewy bodies patients lacking significant tau pathology, extending patent protection through 2042 and driving a 20% share rally. It raised $10 million via sale of 2.5 million shares at $4 each in a direct offering.
1. Patent Allowance Propels Share Rally
CervoMed received a notice of allowance from the U.S. Patent and Trademark Office for its lead candidate neflamapimod in dementia with Lewy bodies patients lacking significant tau pathology. The patent will remain in force until at least 2042 with potential term extensions, bolstering the company’s intellectual property portfolio and triggering a 20% stock increase.
2. $10M Direct Offering to Fund Programs
The company entered definitive agreements to sell 2.5 million shares of common stock at $4.00 per share in a direct registered offering under Nasdaq rules. The $10 million in proceeds are earmarked for ongoing clinical programs and general corporate purposes, with closing expected on June 22 subject to customary conditions.
